2024-514520-16-00RecruitingPhase 1
A Randomized, Double-Blind, Placebo Controlled, Multi - Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis
Liveome Inc.3 sites in 1 country8 target enrollmentStarted: November 18, 2024Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 8
- Locations
- 3
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Sophie Hyun-Ja Ko
Scientific
Liveome Inc.
Study Sites (3)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
A clinical study to compare the effect of Ibrutinib or placebo on prolongation of event free survival in patients with early stage Binet A CLL with a high risk for disease progression defined by various clincial and laboratory risk factors.Patients with Chronic Lymphocytic Leukemia Binet A stage.EUCTR2013-003211-22-DEniversity of Cologne540
Active, not recruiting
Not Applicable
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures. - ELEVATEEUCTR2007-005851-40-BEGlaxoSmithKline Research and Development Ltd500
Active, not recruiting
Not Applicable
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)Resected Squamous Cell Carcinoma of the Head and NeckMedDRA version: 8.1Level: LLTClassification code 10041823Term: Squamous cell carcinomaEUCTR2006-001623-18-LVGlaxoSmithKline Research & Development Limited680
Active, not recruiting
Phase 1
Phase II Study to evaluate Olaparib with Abiraterone in treating metastatic castration resistant prostate cancermetastatic castrate-resistant prostate cancerMedDRA version: 18.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003520-37-CZAstraZeneca AB170
Active, not recruiting
Not Applicable
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)EUCTR2006-001623-18-EEGlaxoSmithKline Research & Development Limited680